Eligibility, any sex, with Gender Dysphoria. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Receipt of Gender Affirming TreatmentPrimary· About 3.5 months
Through a national survey, the investigators will identify receipt of gender-affirming treatment in VA and VA Community Care among transgender and gender diverse Veterans.
Received Hormone Therapy
Group
Value
95% CI
Transgender and Gender Diverse Veterans
769
Received Mental Health Care
Group
Value
95% CI
Transgender and Gender Diverse Veterans
687
Received Hair Removal
Group
Value
95% CI
Transgender and Gender Diverse Veterans
292
Received Prosthetics
Group
Value
95% CI
Transgender and Gender Diverse Veterans
468
Received Vocal Therapy
Group
Value
95% CI
Transgender and Gender Diverse Veterans
350
Received Pre-op Visits
Group
Value
95% CI
Transgender and Gender Diverse Veterans
224
Received Top Surgery
Group
Value
95% CI
Transgender and Gender Diverse Veterans
153
Received Bottom Surgery
Group
Value
95% CI
Transgender and Gender Diverse Veterans
77
Sponsor's own description
Transgender Veterans (trans Vets) frequently experience gender dysphoria or distress related to discord between their gender identity and birth sex. Gender-affirming treatments (GATs) are medically necessary treatments to reduce gender dysphoria. However, not much is known about the barriers and facilitators that influence GAT access and receipt in VA and VA Community Care (CC), among trans Vets who desire GATs. The goals of this mixed-methods study are to determine which GATs trans Vets receive and in which setting, identify barriers and facilitators associated with desired GAT receipt in VA and CC, examine association of GAT receipt, specifically mental healthcare and hormone therapy, with mental health and suicide risk and understand trans Vet experiences related to receipt and desire for mental healthcare and hormone therapy in VA and CC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06969326 — Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy
· Phase 3
· recruiting
NCT07147166 — Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affir
· NA
· recruiting
NCT06639776 — Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons
· recruiting
NCT06639763 — Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients
· recruiting
NCT06351501 — Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria
· Phase 3
· recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care
· Phase 1
· not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran
· NA
· not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness
· NA
· not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
· NA
· not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06615401.